Abstract:
The present disclosure concerns a saw tooth holder for a cutting disk of a rotary cutting machine. The saw tooth holder comprises a holder body having a tooth-receiving surface abuttable against a rear surface of a saw tooth of a tooth assembly and a trailing surface, opposed to the tooth-receiving surface, and defining a trailing oblique angle with respect to the tooth-receiving surface. The holder body has a fastener-receiving aperture extending therethrough between the tooth-receiving surface and the trailing surface and being accessible from the tooth-receiving surface and the trailing surface. The present disclosure also concerns a cutting disk comprising such a saw tooth holder, a saw tooth holder in combination with a tooth assembly, and a rotary cutting machine comprising such a cutting disk.
Abstract:
A saw tooth including a body defining substantially opposed rear and front ends and an axial centerline extending between the rear and front ends, the body defining side faces joined to each other by body edge sections, each side face and each body edge section extending between the rear and front ends; edge cutting tips extending from the body at the front end and facing the direction of advance, each edge cutting tip being in prolongation of a respective one of the body edge sections; and side cutting tips extending from the body and facing the direction of advance, each of the side cutting tips being provided at the front end between two adjacent ones of the edge cutting tips in prolongation of a respective one of the side faces.
Abstract:
A saw tooth mountable to a circular saw disc and including a body defining rear and front ends. In operation, the front end leads the rear end as the saw disc turns. A cutting tip extends from the body and defines a cutting tip base adjacent to the body and an opposed cutting edge. The cutting tip base is rearwardly provided relative to the cutting edge. An elongated gullet extends along the cutting tip substantially adjacent to the cutting tip base and defines opposed gullet first and second ends and a gullet longitudinal axis therebetween. A gullet nadir line extends longitudinally between the gullet first and second ends and joins locations along the gullet that are closest to the rear end at all longitudinal positions along the gullet. The gullet nadir line is closer to the rear end at the gullet first end than at the gullet second end.
Abstract:
The present invention relates to the use of adenosine receptor antagonists, preferably A3 receptor antagonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with overexpression of HIF-1α and/or increased HIF-1α activity (e.g., cancer, respiratory disease). The methods and compositions of the invention are particularly useful for preventing, treating, or ameliorating symptoms associated with a cancer, disease or disorder associated with hypoxia-inducible factor 1α (HIF-1α) using the A3 receptor antagonists of the invention. The present invention provides methods to inhibit the growth of tumors, particularly solid tumors and more particularly hypoxic tumors.
Abstract:
The present invention relates to the use of adenosine receptor agonists, preferably A3 receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with under-expression of HIF-1α and/or decreased HIF-1 α activity (e.g., ischemic related disorders). The methods of the invention are directed to methods of reducing tissue damage (e.g., substantially prevention tissue damage, inducing tissue protection) resulting from ischemia orhypoxia. The invention provides methods for treating, preventing and/or ameliorating one or more symptoms of hypoxic or HIF-1α related disorders by administering an A3 receptor agonist either alone or in combination with other agents.
Abstract translation:本发明涉及腺苷受体激动剂,优选A 3 N 3受体激动剂,单独使用或与其它药剂组合用于治疗,预防和/或控制与低血糖相关的疾病或病症, HIF-1α的表达和/或降低的HIF-1α活性(例如缺血性相关疾病)。 本发明的方法涉及减少由局部缺血或缺氧引起的组织损伤(例如,基本上预防组织损伤,诱导组织保护)的方法。 本发明提供了通过单独或与其它药剂组合施用A 3 O 3受体激动剂来治疗,预防和/或改善一种或多种缺氧或HIF-1α相关疾病症状的方法。